Oppenheimer has recently reiterated Keros Therapeutics Inc (KROS) stock to Outperform rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 16, 2024, Guggenheim had ...
William Blair Small-Mid Cap Core Fund earns an Average Process Pillar rating. The predominant contributor to the rating is the fund's strong long-term risk-adjusted performance. This can be seen ...
"It is my pleasure to welcome Terence to William Blair’s Healthcare investment banking practice and its biopharma group," said Steve Tole, head of Healthcare investment banking at William Blair. "Our ...
William Blair Small Cap Growth Fund earns an Average Process Pillar rating. The leading factor in the rating is the fund's excellent long-term risk-adjusted performance. This can be seen in its ...